List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1781863/publications.pdf Version: 2024-02-01



7HAOFFILIU

#	Article	IF	CITATIONS
1	Integrin α _v β ₃ â€targeted cancer therapy. Drug Development Research, 2008, 69, 329-339.	2.9	267
2	NaGdF ₄ Nanoparticle-Based Molecular Probes for Magnetic Resonance Imaging of Intraperitoneal Tumor Xenografts <i>in Vivo</i> . ACS Nano, 2013, 7, 330-338.	14.6	207
3	Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nature Communications, 2018, 9, 5421.	12.8	184
4	Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes. ACS Nano, 2017, 11, 10147-10158.	14.6	164
5	Ceria Nanoparticles Meet Hepatic Ischemiaâ€Reperfusion Injury: The Perfect Imperfection. Advanced Materials, 2019, 31, e1902956.	21.0	150
6	Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems. Nature Communications, 2018, 9, 5032.	12.8	141
7	Improving Tumor-Targeting Capability and Pharmacokinetics of ^{99m} Tc-Labeled Cyclic RGD Dimers with PEG ₄ Linkers. Molecular Pharmaceutics, 2009, 6, 231-245.	4.6	136
8	68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 947-957.	6.4	132
9	Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours. Nature Biomedical Engineering, 2017, 1, 667-679.	22.5	132
10	¹⁸ F, ⁶⁴ Cu, and ⁶⁸ Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer. Bioconjugate Chemistry, 2009, 20, 1016-1025.	3.6	131
11	18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression. Molecular Imaging and Biology, 2010, 12, 530-538.	2.6	131
12	Improving Tumor Uptake and Pharmacokinetics of64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3and PEG4Linkers. Bioconjugate Chemistry, 2009, 20, 750-759.	3.6	123
13	Small-Animal PET of Tumors with ⁶⁴ Cu-Labeled RGD-Bombesin Heterodimer. Journal of Nuclear Medicine, 2009, 50, 1168-1177.	5.0	118
14	Improving Tumor Uptake and Excretion Kinetics of ⁹⁹ ^m Tc-Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine Linkers. Journal of Medicinal Chemistry, 2008, 51, 7980-7990.	6.4	115
15	Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1296-1307.	6.4	115
16	68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1483-1494.	6.4	114
17	Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using ¹⁸ F-labeled PEGylated RGD-Bombesin Heterodimer ¹⁸ F-FB-PEG ₃ -Glu-RGD-BBN. Journal of Medicinal Chemistry, 2009, <u>5</u> 2, 425-432.	6.4	113
18	^{99m} Tc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study. Journal of Nuclear Medicine, 2012, 53, 716-722.	5.0	112

#	Article	IF	CITATIONS
19	Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. Theranostics, 2016, 6, 627-637.	10.0	92
20	Noninvasive Imaging of CD206-Positive M2 Macrophages as an Early Biomarker for Post-Chemotherapy Tumor Relapse and Lymph Node Metastasis. Theranostics, 2017, 7, 4276-4288.	10.0	85
21	Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials, 2016, 84, 1-12.	11.4	84
22	Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 7330-7339.	7.0	79
23	A Novel Type of Dual-Modality Molecular Probe for MR and Nuclear Imaging of Tumor: Preparation, Characterization and in Vivo Application. Molecular Pharmaceutics, 2009, 6, 1074-1082.	4.6	79
24	The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Nature Communications, 2019, 10, 2914.	12.8	73
25	Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates. Molecular Imaging and Biology, 2011, 13, 730-736.	2.6	69
26	Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Molecular Pharmaceutics, 2019, 16, 339-348.	4.6	66
27	99mTc-Labeled Cyclic RGDfK Dimer:Â Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3Expression. Bioconjugate Chemistry, 2006, 17, 1069-1076.	3.6	65
28	Molecular Imaging of Tumor-Infiltrating Macrophages in a Preclinical Mouse Model of Breast Cancer. Theranostics, 2015, 5, 597-608.	10.0	61
29	Tumor Uptake of the RGD Dimeric Probe ^{99m} Tc-G ₃ -2P ₄ -RGD2 is Correlated with Integrin α _v β ₃ Expressed on both Tumor Cells and Neovasculature. Bioconjugate Chemistry, 2010, 21, 548-555.	3.6	59
30	Noninvasive <i>De novo</i> Imaging of Human Embryonic Stem Cell–Derived Teratoma Formation. Cancer Research, 2009, 69, 2709-2713.	0.9	57
31	^{99m} Tc-Labeled RGD-BBN Peptide for Small-Animal SPECT/CT of Lung Carcinoma. Molecular Pharmaceutics, 2012, 9, 1409-1417.	4.6	56
32	⁶⁸ Ga-PRGD2 PET/CT in the Evaluation of Glioma: A Prospective Study. Molecular Pharmaceutics, 2014, 11, 3923-3929.	4.6	51
33	Integrin α _v β ₆ –Targeted SPECT Imaging for Pancreatic Cancer Detection. Journal of Nuclear Medicine, 2014, 55, 989-994.	5.0	50
34	Linker Effects on Biological Properties of 111In-Labeled DTPA Conjugates of a Cyclic RGDfK Dimer. Bioconjugate Chemistry, 2008, 19, 201-210.	3.6	47
35	HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics, 2019, 9, 2084-2099.	10.0	45
36	^{99m} Tc-Labeled Bombesin(7â^'14)NH ₂ with Favorable Properties for SPECT Imaging of Colon Cancer. Bioconjugate Chemistry, 2008, 19, 1170-1178.	3.6	44

#	Article	IF	CITATIONS
37	Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside. Current Molecular Medicine, 2013, 13, 1487-1505.	1.3	41
38	Integrin Targeted Delivery of Radiotherapeutics. Theranostics, 2011, 1, 201-210.	10.0	39
39	¹⁷⁷ Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. Molecular Pharmaceutics, 2014, 11, 800-807.	4.6	38
40	A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer. Biomaterials, 2015, 53, 229-238.	11.4	38
41	Two ⁹⁰ Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy. Molecular Pharmaceutics, 2011, 8, 591-599.	4.6	36
42	Integrin Imaging with ^{99m} Tc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non–Small Cell Lung Cancer. Radiology, 2016, 281, 958-966.	7.3	34
43	Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab. Molecular Cancer Therapeutics, 2010, 9, 2297-2308.	4.1	31
44	Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. , 2020, 8, e001156.		31
45	Optical Imaging of Integrin α _v β ₃ Expression with Near-Infrared Fluorescent RGD Dimer with Tetra(ethylene glycol) Linkers. Molecular Imaging, 2010, 9, 7290.2009.00032.	1.4	28
46	PET Imaging of Neovascularization with ⁶⁸ Ga-3PRGD ₂ for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy. Molecular Pharmaceutics, 2014, 11, 3915-3922.	4.6	27
47	Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin α _v β ₃ –targeting Radiotracer. Radiology, 2016, 279, 502-512.	7.3	26
48	Anti-tumor Effect of Integrin Targeted ¹⁷⁷ Lu-3PRGD ₂ and Combined Therapy with Endostar. Theranostics, 2014, 4, 256-266.	10.0	25
49	Clinical Translation of a ⁶⁸ Ga-Labeled Integrin α _v β ₆ –Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer. Journal of Nuclear Medicine, 2020, 61, 1461-1467.	5.0	25
50	Dual-Targeted Molecular Probes for Cancer Imaging. Current Pharmaceutical Biotechnology, 2010, 11, 610-619.	1.6	25
51	Specific Targeting of Human Integrin αvβ3 with 111In-Labeled Abegrin™ in Nude Mouse Models. Molecular Imaging and Biology, 2011, 13, 112-120.	2.6	24
52	SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System. Scientific Reports, 2016, 6, 18905.	3.3	24
53	Radioligand saturation binding for quantitative analysis of ligand-receptor interactions. Biophysics Reports, 2015, 1, 148-155.	0.8	22
54	⁶⁸ Ga-Labeled 3PRGD ₂ for Dual PET and Cerenkov Luminescence Imaging of Orthotopic Human Glioblastoma. Bioconjugate Chemistry, 2015, 26, 1054-1060.	3.6	22

#	Article	IF	CITATIONS
55	ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	22
56	Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Molecular Imaging, 2010, 9, 21-9.	1.4	22
57	<i>In-Vitro</i> Internalization and <i>In-Vivo</i> Tumor Uptake of Anti-EGFR Monoclonal Antibody LA22 in A549 Lung Cancer Cells and Animal Model. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 15-24.	1.0	21
58	Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography. Molecular Imaging, 2011, 10, 7290.2010.00041.	1.4	21
59	^{99m} Tc-Labeled Dimeric Octreotide Peptide: A Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors. Molecular Pharmaceutics, 2013, 10, 2925-2933.	4.6	20
60	Molecular imaging of diabetes and diabetic complications: Beyond pancreatic β-cell targeting. Advanced Drug Delivery Reviews, 2019, 139, 32-50.	13.7	20
61	Radioimmunotherapy of Human Colon Cancer Xenografts with ¹³¹ I-Labeled Anti-CEA Monoclonal Antibody. Bioconjugate Chemistry, 2010, 21, 314-318.	3.6	19
62	Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models. Journal of Nuclear Medicine, 2014, 55, 818-823.	5.0	19
63	Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer. Amino Acids, 2010, 39, 111-120.	2.7	18
64	Phage display peptide probes for imaging early response to bevacizumab treatment. Amino Acids, 2011, 41, 1103-1112.	2.7	17
65	Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS oVâ€2. Advanced Science, 2021, 8, e2100965.	11.2	17
66	Molecular imaging of integrin αvβ6 expression in living subjects. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 333-45.	1.0	17
67	Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo. Journal of Nuclear Medicine, 2014, 55, 1002-1007.	5.0	16
68	Chemotherapy-Induced Macrophage Infiltration into Tumors Enhances Nanographene-Based Photodynamic Therapy. Cancer Research, 2017, 77, 6021-6032.	0.9	16
69	Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy. Biomaterials, 2018, 158, 1-9.	11.4	15
70	Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy. Nuclear Medicine and Biology, 2013, 40, 182-189.	0.6	14
71	Small-animal SPECT/CT imaging of cancer xenografts and pulmonary fibrosis using a 99mTc-labeled integrin αvβ6-targeting cyclic peptide with improved in vivo stability. Biophysics Reports, 2018, 4, 254-264.	0.8	14
72	Noninvasive PET tracking of post-transplant gut microbiota in living mice. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 991-1002.	6.4	14

#	Article	IF	CITATIONS
73	Serial in Vivo Imaging Using a Fluorescence Probe Allows Identification of Tumor Early Response to Cetuximab Immunotherapy. Molecular Pharmaceutics, 2015, 12, 10-17.	4.6	12
74	PET Tracers Based on 86Y. Current Radiopharmaceuticals, 2011, 4, 122-130.	0.8	12
75	Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochemical and Biophysical Research Communications, 2006, 349, 816-824.	2.1	11
76	Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1428-1439.	6.4	11
77	Evaluation of 64Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126915.	2.2	11
78	Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy. Journal of Nanobiotechnology, 2021, 19, 175.	9.1	10
79	Phage Display Applications for Molecular Imaging. Current Pharmaceutical Biotechnology, 2010, 11, 603-609.	1.6	10
80	Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy. Journal of Nuclear Medicine, 2016, 57, 321-326.	5.0	8
81	Noninvasive Detection of Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Teratoma with an Integrin-Targeting Agent 99mTc-3PRGD2. Molecular Imaging and Biology, 2013, 15, 58-67.	2.6	7
82	A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2693-2704.	6.4	7
83	^{99m} Tc-Glu-c(RGDyK)-Bombesin SPECT Can Reduce Unnecessary Biopsy of Masses That Are BI-RADS Category 4 on Ultrasonography. Journal of Nuclear Medicine, 2016, 57, 1196-1200.	5.0	6
84	Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. Oncotarget, 2017, 8, 6364-6375.	1.8	6
85	In vivo gamma imaging of the secondary tumors of transplanted human fetal striatum neural stem cells-derived primary tumor cells. NeuroReport, 2008, 19, 1009-1014.	1.2	5
86	Galectin expression detected by 68Ga-galectracer PET as a predictive biomarker of radiotherapy resistance. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	5
87	Technetium 99m–Labeled VQ Peptide: A New Imaging Agent for the Early Detection of Tumors or Premalignancies. Molecular Imaging, 2013, 12, 7290.2012.00047.	1.4	2
88	MicroPET Imaging of Breast Cancer with a Dual-Targeted Molecular Probe ⁶⁸ Ga-RGD-BBN. Sheng Wu Wu Li Hsueh Bao, 2011, 27, 335-344.	0.1	2
89	JFK Is a Hypoxia-Inducible Gene That Functions to Promote Breast Carcinogenesis. Frontiers in Cell and Developmental Biology, 2021, 9, 686737.	3.7	1

90 Editorial (Thematic Issue: Molecular Image-Guided Cancer Treatment: Moving Towards Personalized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

#	Article	IF	CITATIONS
91	RGD-Based Molecular Probes for Integrin $\hat{I}\pm$ v \hat{I}^23 Imaging. Advanced Topics in Science and Technology in China, 2013, , 513-538.	0.1	0

92 Editorial (Thematic Issue: Molecular Image-Guided Cancer Treatment: Moving Towards Personalized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5